

**Quality ID #386: Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences**  
– National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes  
– Meaningful Measure Area: End of Life Care according to Preferences

**2022 COLLECTION TYPE:**  
**MIPS CLINICAL QUALITY MEASURES (CQMS)**

**MEASURE TYPE:**  
Process – High Priority

**DESCRIPTION:**  
Percentage of patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) who were offered assistance in planning for end of life issues (e.g., advance directives, invasive ventilation, hospice) at least once annually.

**INSTRUCTIONS:**  
This measure is to be submitted a minimum of **once per performance period** for patients with a diagnosis of ALS during the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. This measure is appropriate for use in outpatient and long term care (e.g., nursing home, ambulatory). For each of these settings, there should be documentation in the medical record(s) that advance care planning was discussed or documented.

***NOTE:*** Patient encounters for this measure conducted via telehealth (e.g., encounters coded with GQ, GT, 95, or POS 02 modifiers) are allowable.

**Measure Submission Type:**  
Measure data may be submitted by individual MIPS eligible clinicians, groups, or third-party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third-party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third-party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

**DENOMINATOR:**  
All patients with a diagnosis of Amyotrophic Lateral Sclerosis (ALS)

**Denominator Criteria (Eligible Cases):**

**Diagnosis for Amyotrophic Lateral Sclerosis (ICD-10-CM):** G12.21, G12.22, G12.23

**AND**

**Patient encounter during the performance period (CPT):** 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99318, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99345, 99348, 99349, 99350, 99421, 99422, 99423, 99441, 99442, 99443, 99483

**AND NOT**

**DENOMINATOR EXCLUSION:**

**Patient in hospice at any time during the measurement period:** G9758

**NUMERATOR:**  
Patients who were offered assistance in planning for end of life issues (e.g., advance directives, invasive ventilation, or hospice) at least once annually

**Definition:**

**Assistance with end of life issues** – assessment of patient concerns, desires and needs relating to end of life issues. Based on patient’s disease progression this may include discussions regarding invasive ventilation, advance directives and hospice.

**Numerator Options:**

***Performance Met:***

Patient offered assistance with end of life issues during the measurement period (**G9380**)

**OR**

***Performance Not Met:***

Patient not offered assistance with end of life issues during the measurement period (**G9382**)

**RATIONALE:**

Palliative care should be adopted from the time of diagnosis. Many patients are not adequately informed about advance directives and end of life decision making and many hospice workers are not familiar with ALS. Management of the terminal phase of ALS is unsatisfactory in 33% - 61% of cases in Europe and only 8% of palliative care units are involved from the time of diagnosis. The current system of palliative care in the USA is highly decentralized. Between 60-88% of patients die in a medical facility in some countries and not at home, while over 58% of seriously ill ALS patients do not have hospice care. Approaches to end of life care vary widely and are not standardized either in timing or content.

**CLINICAL RECOMMENDATION STATEMENTS:**

- Advance directives for palliative end-of-life care should be discussed early with the patient and carers, respecting the patient's social and cultural background.<sup>1</sup>
- Offer assistance in formulating an advance care directive. (GPP)<sup>2</sup>
- Review the patients’ wishes regarding their care and advance directives regularly. (Level II)<sup>3</sup>
- Re-discuss the patient’s preferences for life-sustaining treatments every 6 months. (GPP)<sup>2</sup>
- Initiate discussions on end-of-life issues whenever the patient asks or “opens the door” for end-of-life information and/or interventions. (GPP) <sup>2</sup>Treat pain in ALS following accepted guidelines. (GPP)<sup>2</sup>
- Initiate early referral to hospice or home care teams well in advance of the terminal phase of ALS to facilitate the work of the hospice team. (GPP)<sup>2</sup>
- Discuss options for respiratory support and end-of-life issues if the patient has dyspnea, other symptoms of hypoventilation or VC <50%. (GPP)<sup>2</sup>
- Treat terminal dyspnea and/or pain with opioids alone or in combination with benzodiazepines if anxiety is present.(GPP)<sup>2</sup>

1. Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force. *Eur J Neurol* 2011; 19(3) 360-375 (GPP=Good Practice Point)
2. Andersen PM, Borasio GD, Dengler R, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. *European J of Neurology* 2005; 12:921-938 (GPP=Good Practice Point)
3. Heffernan C., Jenkinson C, Holmes T, et al. Management of respiration in MND/ALS patients: An evidence based review. *Amyotrophic Lateral Sclerosis* 2006; 7(1):5-15

**COPYRIGHT:**

Quality Measures published by the American Academy of Neurology Institute and its affiliates are assessments of current scientific and clinical information provided as an educational service. The information: 1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; 2) is not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); 3) addresses only the question(s) or topic(s) specifically identified; 4) does not mandate any particular course of medical care; and 5) is not intended to substitute for the

independent professional judgment of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. AANI provides this information on an “as is” basis, and makes no warranty, expressed or implied, regarding the information. AANI specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. AANI assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.


© 2022 American Academy of Neurology Institute All rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary coding sets should obtain all necessary licenses from the owners of these code sets. The AAN and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measures specifications is copyright 2004 – 2022 American Medical Association. G codes and associated descriptions included in these Measure specifications are in the public domain.

## 2022 Clinical Quality Measure Flow for Quality ID #386: Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences

*Disclaimer: Refer to measure specification for specific coding and instructions to submit this measure.*



**SAMPLE CALCULATIONS**

**Data Completeness=**  

$$\frac{\text{Performance Met (a=50 patients)} + \text{Performance Not Met (c=20 patients)}}{\text{Eligible Population / Denominator (d=80 patients)}} = \frac{70 \text{ patients}}{80 \text{ patients}} = 87.50\%$$

**Performance Rate=**  

$$\frac{\text{Performance Met (a=50 patients)}}{\text{Data Completeness Numerator (70 patients)}} = \frac{50 \text{ patients}}{70 \text{ patients}} = 71.43\%$$

\*See the posted measure specification for specific coding and instructions to submit this measure.  
 NOTE: Submission Frequency: Patient-Process

CPT only copyright 2021 American Medical Association. All rights reserved.  
 The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.

v6

## 2022 Clinical Quality Measure Flow Narrative for Quality ID #386: Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences

**Disclaimer:** Refer to the measure specification for specific coding and instructions to submit this measure.

1. Start with Denominator
2. Check *Diagnosis for Amyotrophic Lateral Sclerosis (ALS) as listed in Denominator\**:
  - a. If *Diagnosis for Amyotrophic Lateral Sclerosis (ALS) as listed in Denominator\** equals No, do not include in *Eligible Population/Denominator*. Stop processing.
  - b. If *Diagnosis for Amyotrophic Lateral Sclerosis (ALS) as listed in Denominator\** equals Yes, proceed to check *Patient encounter during the performance period as listed in Denominator\**.
3. Check *Patient encounter during the performance period as listed in Denominator\**:
  - a. If *Patient encounter during the performance period as listed in Denominator\** equals No, do not include in *Eligible Population/Denominator*. Stop processing.
  - b. If *Patient encounter during the performance period as listed in Denominator\** equals Yes, proceed to check *Patient in hospice at any time during measurement period*.
4. Check *Patient in hospice at any time during measurement period*:
  - a. If *Patient in hospice at any time during measurement period* equals Yes, do not include in *Eligible Population/Denominator*. Stop processing.
  - b. If *Patient in hospice at any time during measurement period* equals No, include in *Eligible Population/Denominator*.
5. Denominator Population:
  - Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation.
6. Start Numerator
7. Check *Patient offered assistance with end of life issues during measurement period*:
  - a. If *Patient offered assistance with end of life issues during measurement period* equals Yes, include in *Data Completeness Met and Performance Met*.
    - *Data Completeness Met and Performance Met* letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 50 patients in the Sample Calculation.
  - b. If *Patient offered assistance with end of life issues during measurement period* equals No, proceed to check *Patient not offered assistance with end of life issues during measurement period*.
8. Check *Patient not offered assistance with end of life issues during measurement period*:
  - a. If *Patient not offered assistance with end of life issues during measurement period* equals Yes, include in the *Data Completeness Met and Performance Not Met*.

- *Data Completeness Met and Performance Not Met* letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 patients in the Sample Calculation.
- b. If *Patient not offered assistance with end of life issues during measurement period* equals No, proceed to check *Data Completeness Not Met*.
9. Check *Data Completeness Not Met*:
- If *Data Completeness Not Met*, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

### **Sample Calculations**

Data Completeness equals Performance Met (a equals 50 patients) plus Performance Not Met (c equals 20 patients) divided by Eligible Population/Denominator (d equals 80 patients). All equals 70 patients divided by 80 patients. All equals 87.50 percent.

Performance Rate equals Performance Met (a equals 50 patients) divided by Data Completeness Numerator (70 patients). All equals 50 patients divided by 70 patients. All equals 71.43 percent.

\*See the posted measure specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Patient-Process

The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.